— Know what they know.
Not Investment Advice

IRD NASDAQ

Opus Genetics, Inc.
1W: -13.7% 1M: -31.5% 3M: -0.3% YTD: +63.2% 1Y: +73.9% 3Y: +16.5% 5Y: -17.8%
$3.46
+0.14 (+4.22%)
 
Weekly Expected Move ±9.9%
$3 $3 $3 $4 $4
NASDAQ · Healthcare · Biotechnology · Tech Score Strong Sell · Power 32 · $287.9M mcap · 35M float · 5.99% daily turnover · Short 61% of daily vol
Credit Risk of going bust: higher than 69% of companies Debt: 10.8% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.06 (down 98%), Opus Genetics, Inc. would be worth roughly what it owes.
Total debt $34.9M against a stock market value of $287.9M.
Distance to default 3.48 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $17.5M (short-term plus half of long-term), stock volatility 79.7%; Altman Z'' -10.91. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

📊 Key Metrics

TTM
$10M
Revenue
-36.1% YoY
$-108M
Net Income
-84.7% YoY
$-41M
Free Cash Flow
-27.8% YoY
100.0%
Gross Margin
-2182.8%
Op. Margin
-1072.6%
Net Margin

💰 Income Flow

How revenue becomes profit

💵 Cash Flow

⚠️ Cash Burn Where cash goes

🏦 Balance Sheet

Assets = Liabilities + Equity

📈 Financial Health

Profitability

ROE-4796.5%
ROA-163.5%
ROIC59.8%

Valuation

P/E-2.7
P/B-25.4
EV/EBITDA-3.9

Leverage

Debt/Equity-2.69
Current Ratio12.19
Interest Cov.-39.6x

Quality Scores

Piotroski F3/9
Altman Z-3.88
Beneish M-7.74

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms